title: Failure of neonatal clomipramine treatment to alter forced swim immobility: chronic treadmill or activity-wheel running and imipramine.
abstract: We examined whether chronic running on a treadmill or activity wheel would attenuate the increased swim immobility that has been reported after neonatal clomipramine (CLI) treatment. Male Sprague-Dawley pups (N = 60) were injected with the monoamine reuptake inhibitor clomipramine hydrochloride (40 mg/kg per day i.p.) from 8 to 21 days of age. Another group (N = 12) received saline vehicle. At age 4 weeks, the CLI pups were randomly assigned to experimental conditions: (1) sedentary; (2) 24-h access to an activity wheel; (3) sedentary that received the antidepressant drug imipramine hydrochloride (10 mg/kg twice daily) during the last 10 days of the experiment; (4) activity wheel + imipramine; (5) treadmill running (30 m/min for 1 h at 0 degrees incline, 6 days/week). At age 16 weeks, rats underwent the Porsolt swim test 48 h after the last imipramine injection and/or the last exercise session. The increase in swim immobility among CLI-treated rats was small (one quarter of SD) and not statistically significant (p>0.10). The results are not consistent with our previous finding of antidepressant-like effects of activity-wheel running based on brain noradrenergic adaptations and enhanced male copulatory performance after neonatal CLI treatment. The lack of change in swim performance after clomipramine questions the generalizability of the CLI model of depression and the validity of the forced swim test as a behavioral measure of depression when it is used after neonatal CLI injection or chronic activity-wheel running.
authors.affiliation: Department of Exercise Science, The University of Georgia, Ramsey Student Center, 300 River Road, Athens, GA 30602-6554, USA.
authors.forename: H S
authors.initials: HS
authors.lastname: Yoo
authors.forename: B N
authors.initials: BN
authors.lastname: Bunnell
authors.forename: J B
authors.initials: JB
authors.lastname: Crabbe
authors.forename: L R
authors.initials: LR
authors.lastname: Kalish
authors.forename: R K
authors.initials: RK
authors.lastname: Dishman
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology*; D001835:Body Weight / Q000502:physiology; D002997:Clomipramine / Q000494:pharmacology*; D005260:Female; D007099:Imipramine / Q000494:pharmacology*; D007103:Immobilization; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009638:Norepinephrine / Q000097:blood / Q000502:physiology; D010805:Physical Conditioning, Animal; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D013550:Swimming / Q000523:psychology*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000929:Antidepressive Agents, Tricyclic; D002997:Clomipramine; D007099:Imipramine; D009638:Norepinephrine; D017367:Selective Serotonin Reuptake Inhibitors